We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$9.39B
$11.3M 0.1%
45,515
– –
ACHN
52
DELISTED
Achillion Pharmaceuticals
ACHN
$10.6M 0.09%
2,856,637
– –
CPRX
53
DELISTED
Catalyst Pharmaceutical
CPRX
$10.5M 0.09%
4,381,072
-1,471,081
-25% -$4.89M
VNDA icon
54
Vanda Pharmaceuticals
VNDA
$319M
$10.1M 0.09%
600,354
+176,470
+42% +$2.95M
ASMB icon
55
Assembly Biosciences
ASMB
$700M
$9.52M 0.08%
16,149
-10,745
-40% -$6.66M
ANAB icon
56
AnaptysBio
ANAB
$1.71B
$9.48M 0.08%
91,086
-90,300
-50% -$10.2M
MGNX icon
57
MacroGenics
MGNX
$261M
$9.15M 0.08%
363,676
– –
CBIO
58
Crescent Biopharma
CBIO
$637M
$9.14M 0.08%
5,633
– –
RIGL icon
59
Rigel Pharmaceuticals
RIGL
$857M
$8.92M 0.08%
251,888
– –
FOMX
60
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$8.2M 0.07%
1,598,991
-867,711
-35% -$5.22M
GNMX
61
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8.15M 0.07%
4,055,142
– –
ALBO
62
DELISTED
Albireo Pharma Inc
ALBO
$8.14M 0.07%
250,000
+50,000
+25% +$1.68M
SYRS
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$7.46M 0.06%
57,484
– –
XLRN
64
DELISTED
Acceleron Pharma
XLRN
$6.41M 0.05%
163,900
– –
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.28M 0.05%
+169,492
New +$4.52M
ALKS icon
66
Alkermes
ALKS
$8.11B
$5.81M 0.05%
100,251
-50,000
-33% -$2.93M
IFRX icon
67
InflaRx
IFRX
$309M
$5.77M 0.05%
200,000
– –
FSTX
68
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.74M 0.05%
93,286
– –
CCXI
69
DELISTED
ChemoCentryx, Inc.
CCXI
$5.63M 0.05%
414,029
+364,965
+744% +$3.77M
MNTA
70
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$5.6M 0.05%
+308,500
New +$5.14M
NBRV
71
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$4.72M 0.04%
3,753
– –
LJPC
72
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.61M 0.04%
154,675
– –
SLDB icon
73
Solid Biosciences
SLDB
$997M
$4.41M 0.04%
+39,192
New +$13.2M
STML
74
DELISTED
Stemline Therapeutics, Inc.
STML
$4.4M 0.04%
287,827
-345,670
-55% -$5.39M
NVAX icon
75
Novavax
NVAX
$1.47B
$4.2M 0.04%
100,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2018 Portfolio in Review

As of Q1 2018, Julian Baker held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Julian Baker deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was Yarrow Bioscience: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Julian Baker's largest Q1 2018 buy was Yarrow Bioscience: 194 shares worth $26.3M.
  • Julian Baker added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Julian Baker's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Julian Baker fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Julian Baker's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Julian Baker opened 5 new positions and closed 13 in Q1 2018.
  • Julian Baker's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.